Iris Teruel

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

BRCA1 c.68_69del as a founder variant in the Spanish Roma: prevalence and screening implications.

BRCA1 c.68_69del as a founder variant in the Spanish Roma: prevalence and screening implications.

Journal: European journal of human genetics : EJHG

Published: February 08, 2026

Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.

Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.

Journal: Clinical and translational medicine

Published: May 20, 2025

Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled Analysis.

Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled Analysis.

Journal: The Laryngoscope

Published: April 04, 2025

Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Journal: International journal of molecular sciences

Published: September 17, 2024

Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.

Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer.

Journal: Therapeutic advances in medical oncology

Published: July 13, 2024

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.

Journal: ESMO open

Published: March 04, 2024

SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.

SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: August 07, 2023

Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery.

Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery.

Journal: International journal of molecular sciences

Published: June 05, 2023

Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?

Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?

Journal: Exploration of targeted anti-tumor therapy

Published: April 21, 2023

SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis.

SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis.

Journal: Frontiers in immunology

Published: November 30, 2022

Small Cell Carcinoma of the Vagina: First Systematic Review of Case Reports and Proposal of a Management Algorithm.

Small Cell Carcinoma of the Vagina: First Systematic Review of Case Reports and Proposal of a Management Algorithm.

Journal: Journal of lower genital tract disease

Published: October 25, 2022

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.

Journal: Cancers

Published: July 22, 2022

Showing 1-12 of 17

Last Updated: 09/26/2026